LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 127

Search options

  1. Article ; Online: Supporting Imaging at the Highest Level: Janet Eary Talks with Lale Kostakoglu About NCI Leadership in Advancing Imaging.

    Eary, Janet / Kostakoglu, Lale

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2024  

    Language English
    Publishing date 2024-04-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.124.267727
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Defining Myeloma and Advancing Treatment Options: A Conversation Between S. Vincent Rajkumar and Lale Kostakoglu.

    Rajkumar, S Vincent / Kostakoglu, Lale

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2023  Volume 64, Issue 6, Page(s) 831–834

    MeSH term(s) Humans ; Multiple Myeloma/diagnostic imaging ; Multiple Myeloma/therapy ; Communication
    Language English
    Publishing date 2023-05-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.123.265877
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Precision Medicine Clinical Trials: A Conversation Between Peter O'Dwyer and Lale Kostakoglu.

    O'Dwyer, Peter J / Kostakoglu, Lale

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2022  Volume 63, Issue 6, Page(s) 808–811

    MeSH term(s) Clinical Trials as Topic ; Humans ; Precision Medicine
    Language English
    Publishing date 2022-05-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.121.264320
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Guest Editorial.

    Kostakoglu, Lale

    Seminars in nuclear medicine

    2017  Volume 48, Issue 1, Page(s) 2–3

    MeSH term(s) Fluorodeoxyglucose F18 ; Humans ; Image Processing, Computer-Assisted ; Lymphoma/diagnostic imaging ; Positron Emission Tomography Computed Tomography
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2017-10-27
    Publishing country United States
    Document type Editorial
    ZDB-ID 120248-0
    ISSN 1558-4623 ; 0001-2998
    ISSN (online) 1558-4623
    ISSN 0001-2998
    DOI 10.1053/j.semnuclmed.2017.10.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reply: Fact Sheet About Interim and End-of-Treatment

    Kostakoglu, Lale

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2017  Volume 58, Issue 7, Page(s) 1179

    MeSH term(s) Fluorodeoxyglucose F18 ; Humans ; Lymphoma ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2017-04-06
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.117.190512
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma.

    Kostakoglu, Lale / Chauvie, Stéphane

    PET clinics

    2019  Volume 14, Issue 3, Page(s) 317–329

    Abstract: Lymphoma is a potentially curable disease; however, the clinical challenge lies in further improvement of outcomes. PET with fludeoxyglucose is an effective imaging tool. PET-derived quantitative metrics have raised significant interest to be used as a ... ...

    Abstract Lymphoma is a potentially curable disease; however, the clinical challenge lies in further improvement of outcomes. PET with fludeoxyglucose is an effective imaging tool. PET-derived quantitative metrics have raised significant interest to be used as a prognostic factor to complement clinical parameters for treatment decisions. The most optimized use of these quantitative PET metrics, however, will be possible with the standardization of imaging procedures. In this article, we review the technical and methodological considerations related to PET-derived quantitative metrics, and the relevant published data to emphasize the potential value of these metrics in patient prognosis and treatment response in lymphoma.
    MeSH term(s) Evaluation Studies as Topic ; Fluorodeoxyglucose F18 ; Humans ; Lymphoma/diagnostic imaging ; Lymphoma/therapy ; Positron-Emission Tomography/methods ; Prognosis ; Radiopharmaceuticals ; Treatment Outcome
    Chemical Substances Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2019-05-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2764575-7
    ISSN 1879-9809 ; 1556-8598
    ISSN (online) 1879-9809
    ISSN 1556-8598
    DOI 10.1016/j.cpet.2019.03.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.

    Kostakoglu, Lale / Nowakowski, Grzegorz S

    PET clinics

    2019  Volume 14, Issue 3, Page(s) 307–315

    Abstract: PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection ... ...

    Abstract "PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS."
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Fluorodeoxyglucose F18 ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Positron Emission Tomography Computed Tomography/methods ; Radiopharmaceuticals ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2019-05-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2764575-7
    ISSN 1879-9809 ; 1556-8598
    ISSN (online) 1879-9809
    ISSN 1556-8598
    DOI 10.1016/j.cpet.2019.03.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Radionuclide response assessment of breast cancer.

    Kostakoglu, Lale

    Seminars in nuclear medicine

    2013  Volume 43, Issue 4, Page(s) 299–316

    Abstract: Preoperative systemic therapy with cytotoxic or biologic anticancer regimens has gained significant popularity in the management of breast cancer. Moreover, there is a worldwide paradigm shift toward an individualized approach to identify predictive ... ...

    Abstract Preoperative systemic therapy with cytotoxic or biologic anticancer regimens has gained significant popularity in the management of breast cancer. Moreover, there is a worldwide paradigm shift toward an individualized approach to identify predictive surrogate markers for stratifying patients into distinct subgroups to improve outcome after neoadjuvant or adjuvant therapy. Although achievement of pathologic complete response constitutes the gold standard for assessing therapeutic efficacy only a minority of patients achieve a pathologic complete response. Imaging has evolved to play a crucial role in monitoring treatment effectiveness, particularly, early during therapy. There is mounting evidence that (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a more superior metabolic imaging modality than anatomic modalities for assessment of the response during or at completion of treatment. Ultimately, the prediction of therapeutic effectiveness or survival or both by FDG-PET imaging could successfully tailor treatment and avoid unnecessary toxicities. This paper provides an overview of current use and the main indications of FDG-PET and integrated PET/computed tomography in response assessment of breast cancer as well as the future directions for the management using non-FDG-based tracers developed against specific targets.
    MeSH term(s) Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Cell Proliferation ; Humans ; Neoplasm Metastasis ; Radionuclide Imaging/methods ; Treatment Outcome
    Language English
    Publishing date 2013-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 120248-0
    ISSN 1558-4623 ; 0001-2998
    ISSN (online) 1558-4623
    ISSN 0001-2998
    DOI 10.1053/j.semnuclmed.2013.03.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Novel PET Radiotracers for Potential Use in Management of Lymphoma.

    Kostakoglu, Lale

    PET clinics

    2012  Volume 7, Issue 1, Page(s) 83–117

    Abstract: This article discusses possible roles for emerging novel positron emission tomography (PET) radiotracers for diagnosis and follow-up of lymphomas. Novel imaging probes are being developed to fulfill the need of a more specific radiopharmaceutical to ... ...

    Abstract This article discusses possible roles for emerging novel positron emission tomography (PET) radiotracers for diagnosis and follow-up of lymphomas. Novel imaging probes are being developed to fulfill the need of a more specific radiopharmaceutical to target subcomponents of tumor microenvironment to individualize management approaches. Noninvasive molecular imaging probes are being developed to revolutionize characterization of tumor biology and response to therapy in more specific ways for the host, tumor microenvironment, and therapeutic regimens. The new clinical PET probes seem promising in fostering clinical gains that would lead to better survival outcomes, although further studies are warranted to prove a role in the management of lymphomas.
    Language English
    Publishing date 2012-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2764575-7
    ISSN 1879-9809 ; 1556-8598
    ISSN (online) 1879-9809
    ISSN 1556-8598
    DOI 10.1016/j.cpet.2011.12.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Metabolic Tumor Volume Metrics in Lymphoma.

    Kostakoglu, Lale / Chauvie, Stéphane

    Seminars in nuclear medicine

    2018  Volume 48, Issue 1, Page(s) 50–66

    Abstract: Although visual assessment using the Deauville criteria is strongly recommended by guidelines for treatment response monitoring in all FDG-avid lymphoma histologies, the high rate of false-positives and concerns about interobserver variability have ... ...

    Abstract Although visual assessment using the Deauville criteria is strongly recommended by guidelines for treatment response monitoring in all FDG-avid lymphoma histologies, the high rate of false-positives and concerns about interobserver variability have motivated the development of quantitative tools to facilitate objective measurement of tumor response in both routine and clinical trial settings. Imaging studies using functional quantitative measures play a significant role in profiling oncologic processes. These quantitative metrics allow for objective end points in multicenter clinical trials. However, the standardization of imaging procedures including image acquisition parameters, reconstruction and analytic measures, and validation of these methods are essential to enable an individualized treatment approach. A robust quality control program associated with the inclusion of proper scanner calibration, cross-calibration with dose calibrators and across other scanners is required for accurate quantitative measurements. In this section, we will review the technical and methodological considerations related to PET-derived quantitative metrics and the relevant published data to emphasize the potential value of these metrics in the prediction of patient prognosis in lymphoma.
    MeSH term(s) Humans ; Image Processing, Computer-Assisted ; Lymphoma/diagnostic imaging ; Lymphoma/metabolism ; Lymphoma/pathology ; Positron-Emission Tomography ; Tumor Burden
    Language English
    Publishing date 2018
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 120248-0
    ISSN 1558-4623 ; 0001-2998
    ISSN (online) 1558-4623
    ISSN 0001-2998
    DOI 10.1053/j.semnuclmed.2017.09.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top